PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ PEP-Therapy, a clinical-stage biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and Institut Curie,.
Wefight raises 10 million euros to accelerate its growth and expand internationally sandiegosun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandiegosun.com Daily Mail and Mail on Sunday newspapers.
Wefight raises 10 million euros to accelerate its growth and expand internationally texasguardian.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from texasguardian.com Daily Mail and Mail on Sunday newspapers.
as well as a €1 million loan from Bpifrance
PARIS, July 19, 2021 /PRNewswire/
PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of cancers, announced today that it raised an additional €2.6 million ($3 million) in an extension of its Series A financing round, bringing the total raised in this round to €5.4 million ($6.4 million). This new funding comprises €1.6 million in equity from Anaxago, i&i Prague and BADGE as well as a €1 million loan from Bpifrance.
This increased financial support highlights the potential of PEP-010, as well as PEP-Therapy s Cell Penetrating & Interfering Peptide (CP&IP) technology platform, which was first developed at Sorbonne University and Institut Curie.